title: Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.
abstract: Protein kinase inhibitors have proved to be effective and well tolerated in special form of malignant diseases in which targeted kinases play a central role in the development and progression of the malignant clone. In addition, the development of acquired drug resistance, due to new mutations or clonal evolution, during treatment is common. Methods for measuring the activity and predicting the efficacy of such compounds are warranted for evaluating individual responses to treatment, particularly in a context of widespread preclinical and clinical studies of protein kinase inhibitors in patients with heterogeneous myeloid malignancies.
authors.affiliation: Haukeland University Hospital, Division for Hematology, Department of Medicine , N-5021 Bergen , Norway +55 97 50 00 ; +55 97 29 50 ; Hakon.Reikvam@med.uib.no.
authors.forename: Håkon
authors.initials: H
authors.lastname: Reikvam
authors.forename: Ina
authors.initials: I
authors.lastname: Nepstad
authors.forename: Jerome
authors.initials: J
authors.lastname: Tamburini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors